GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Biosyent Inc (TSXV:RX) » Definitions » Enterprise Value

Biosyent (TSXV:RX) Enterprise Value : C$111.19 Mil (As of Nov. 12, 2024)


View and export this data going back to 1979. Start your Free Trial

What is Biosyent Enterprise Value?

Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Biosyent's Enterprise Value is C$111.19 Mil. Biosyent's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 was C$9.54 Mil. Therefore, Biosyent's EV-to-EBIT ratio for today is 11.66.

EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Biosyent's Enterprise Value is C$111.19 Mil. Biosyent's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 was C$10.01 Mil. Therefore, Biosyent's EV-to-EBITDA ratio for today is 11.11.

EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Biosyent's Enterprise Value is C$111.19 Mil. Biosyent's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 was C$33.82 Mil. Therefore, Biosyent's EV-to-Revenue ratio for today is 3.29.


Biosyent Enterprise Value Historical Data

The historical data trend for Biosyent's Enterprise Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biosyent Enterprise Value Chart

Biosyent Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Enterprise Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only 62.42 77.42 77.06 57.38 83.29

Biosyent Quarterly Data
Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24
Enterprise Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 62.53 64.42 83.29 78.55 99.58

Competitive Comparison of Biosyent's Enterprise Value

For the Drug Manufacturers - Specialty & Generic subindustry, Biosyent's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biosyent's Enterprise Value Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Biosyent's Enterprise Value distribution charts can be found below:

* The bar in red indicates where Biosyent's Enterprise Value falls into.



Biosyent Enterprise Value Calculation

Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.

Biosyent's Enterprise Value for the fiscal year that ended in Dec. 2023 is calculated as

Biosyent's Enterprise Value for the quarter that ended in Jun. 2024 is calculated as

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent  (TSXV:RX) Enterprise Value Explanation

When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.

If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.

The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.

For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.

Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.

1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.

Biosyent's EV-to-EBIT for today is

EV-to-EBIT=Enterprise Value (Today)/EBIT (TTM)
=111.185/9.537
=11.66

Biosyent's current Enterprise Value is C$111.19 Mil.
Biosyent's EBIT for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$9.54 Mil.

2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.

Biosyent's EV-to-EBITDA for today is:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA(TTM)
=111.185/10.007
=11.11

Biosyent's current Enterprise Value is C$111.19 Mil.
Biosyent's EBITDA for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$10.01 Mil.

3. EV-to-Revenue is calculated as Enterprise Value divided by its Revenue.

Biosyent's EV-to-Revenue for today is:

EV-to-Revenue=Enterprise Value (Today)/Revenue (TTM)
=111.185/33.824
=3.29

Biosyent's current Enterprise Value is C$111.19 Mil.
Biosyent's Revenue for the trailing twelve months (TTM) ended in Jun. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was C$33.82 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biosyent Enterprise Value Related Terms

Thank you for viewing the detailed overview of Biosyent's Enterprise Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Biosyent Business Description

Traded in Other Exchanges
Address
2476 Argentia Road, Suite 402, Toronto, Mississauga, ON, CAN, L5N 6M1
Biosyent Inc is a Canada-based growth-oriented specialty pharmaceutical company. It has focused on in-licensing or acquiring originative pharmaceuticals and other healthcare products. Its product includes FeraMAX 150, Cathejell Jelly, FeraMAX Powder, RepaGyn, Proktis-M, Repagyn, and Tibella.m.
Executives
Peter Douglas Lockhard Director
Seyed Ahmad Ashrafi Director
Sharan Raghubir Senior Officer
Rene Goehrum 10% Security Holder, Director, Senior Officer
Biosyent Inc. Issuer
Joost Van Der Mark Senior Officer
Robert Joseph March Senior Officer
Sara Elford Director
Alfred D'souza Director

Biosyent Headlines

No Headlines